Ando, M.; Kato, A.; Kimura, M.; Ogura, S.; Kuwayama, S.; Kominami, A.; Kuwayama, S.; Obayashi, T.; Ando, R.; Monoe, T.;
et al. Effects of Combination Therapy with Intravitreal Ranibizumab and Tissue Plasminogen Activator for Neovascular Age-Related Macular Degeneration. J. Clin. Med. 2024, 13, 2417.
https://doi.org/10.3390/jcm13082417
AMA Style
Ando M, Kato A, Kimura M, Ogura S, Kuwayama S, Kominami A, Kuwayama S, Obayashi T, Ando R, Monoe T,
et al. Effects of Combination Therapy with Intravitreal Ranibizumab and Tissue Plasminogen Activator for Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine. 2024; 13(8):2417.
https://doi.org/10.3390/jcm13082417
Chicago/Turabian Style
Ando, Michiko, Aki Kato, Masayo Kimura, Shuntaro Ogura, Soichiro Kuwayama, Aoi Kominami, Satoshi Kuwayama, Tomohiro Obayashi, Ryota Ando, Takafumi Monoe,
and et al. 2024. "Effects of Combination Therapy with Intravitreal Ranibizumab and Tissue Plasminogen Activator for Neovascular Age-Related Macular Degeneration" Journal of Clinical Medicine 13, no. 8: 2417.
https://doi.org/10.3390/jcm13082417
APA Style
Ando, M., Kato, A., Kimura, M., Ogura, S., Kuwayama, S., Kominami, A., Kuwayama, S., Obayashi, T., Ando, R., Monoe, T., Morita, H., & Yasukawa, T.
(2024). Effects of Combination Therapy with Intravitreal Ranibizumab and Tissue Plasminogen Activator for Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 13(8), 2417.
https://doi.org/10.3390/jcm13082417
